# Bristol Myers Squibb 執行長表示澳洲有被新藥市場拋棄的風險。

*biotech · news · 2026-06-01 · Australian Financial Review*

## Key points

- Bristol Myers Squibb 警告澳洲可能被拋棄為新藥市場。
- 澳洲的定價與審批制度被視為全球最嚴苛之一。
- 現行制度對藥廠上市新藥幾乎沒有商業誘因。
- 數百萬澳洲患者可能因這些障礙而無法獲得負擔得起的救命療法。

One of the world’s biggest drug companies says Australia risks being abandoned as a market for new medicines because it has one of the world’s most prohibitive pricing and approvals systems that may cause millions of patients to lose out on affordable live-saving therapies. Owen Smith, the CEO of Bristol Myers Squibb’s Australian operations, said on Monday the Albanese government needed to urgently reform a pricing system which provided little commercial incentive for drugmakers to get new medicines listed on the Pharmaceutical Benefits Scheme. Loading...

**Companies:** Bristol Myers Squibb
**Countries:** Australia

[Read the full story on Australian Financial Review](https://www.afr.com/companies/healthcare-and-fitness/us-big-pharma-vents-over-australia-s-drug-pricing-and-approvals-20260528-p601s1)

---

Canonical: https://newsio.io/zh-TW/n/59511d63-ec71-4c06-9d42-f141ad5d2f24/bristol-myers-squibb-owen-smith-albanese
Summarized by Newsio from Australian Financial Review. https://newsio.io/how-it-works